This inventor holds 2 USPTO granted patents and 4 published patent applications. Top assignee: Pfizer Corporation. Active years: 2019-2025.
Company Filing History:
Years Active: 2019-2025
Title: Albert Myung Kim: Innovator in Medical Treatments
Introduction
Albert Myung Kim is a notable inventor based in Newton, MA (US). He has made significant contributions to the field of medical treatments, particularly in addressing liver diseases and cholesterol management. With a total of 2 patents, his work reflects a commitment to advancing healthcare solutions.
Latest Patents
Kim's latest patents include innovative methods for treating non-alcoholic fatty liver disease (NAFLD) and related disorders. One of his patents describes a method for treating fatty liver disease using a composition that includes specific dosages of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid. Another patent focuses on therapeutic dosing regimens utilizing anti-PCSK9 antibodies to treat disorders characterized by elevated low-density lipoprotein cholesterol (LDL-C) levels in patients.
Career Highlights
Albert Myung Kim is currently associated with Pfizer Corporation, a leading global pharmaceutical company. His work at Pfizer has allowed him to collaborate with other experts in the field, enhancing the impact of his inventions on patient care.
Collaborations
Some of Kim's notable coworkers include Anne Barbara Cropp and David Raymond Plowchalk. Their collaborative efforts contribute to the innovative environment at Pfizer, fostering advancements in medical treatments.
Conclusion
Albert Myung Kim's contributions to medical innovations, particularly in the treatment of liver diseases and cholesterol management, highlight his role as a significant inventor in the healthcare industry. His patents reflect a dedication to improving patient outcomes through innovative therapies.